Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Can-Fite BioPharma announced progress in the regulatory status of its lead drug candidates, Namodenoson and Piclidenoson, both in Phase III clinical trials targeting liver cancer (HCC) and moderate-to-severe plaque psoriasis. Namodenoson holds FDA Fast Track and Orphan Drug designations in the US and Europe, providing accelerated pathways toward ma…